10. HLA class II Immunogenic Mutation Burden predicts response to immune checkpoint blockade

HLA class I immunogenic mutations (IMM) have been previously studied as prognostic biomarkers for immune-checkpoint blockade (ICB) treatments, while HLA class II IMMs remain unexplored. We characterized the impact of HLA class II restricted IMMs on prognosis by analyzing the HLA class II IMM landscape of four ICB-treated cohorts in non-small cell lung cancer (NSCLC)(n=123) and melanoma (n=110). Using MHCnuggets, a neural-network based model, and whole-exome sequencing data, we identified 5,639 HLA class II IMMs across the four cohorts.

Source: Cancer Genetics and Cytogenetics - November 1, 2022 Category: Genetics & Stem Cells Authors: Xiaoshan Shao, Justin Huang, Noushin Niknafs, Archana Balan, Christopher Cherry, James White, Victor Velculescu, Valsamo Anagnostou, Rachel Karchin Source Type: research